Overview

Gender

male

Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics. Until end of April 2016 he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Previously he was the Senior VP Biologics at Shanghai ChemPartner, where he established comprehensive biologics R&D capabilities.

Before that he was a Volwiler Associate Fellow at Abbott laboratories, USA. Dr. Wu has extensive experience in engineering and development of therapeutic monoclonal antibodies. He is also the primary inventor of the DVD-Ig technology, a new bi-specific antibody platform for developing next generation biologics therapies. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral training at Harvard Medical School.